PEAR

Pear Therapeutics, Inc. is a commercial-phase medical company focused on inventing and distributing digital therapeutics. Its current offerings include reSET, which addresses substance use disorders involving alcohol, cannabis, cocaine, and stimulants; reSET-O, prescribed alongside buprenorphine for opioid use disorder; and Somryst, a digital solution for chronic insomnia. Beyond these marketed therapies, the company maintains a robust development pipeline of 14 prospective products. These investigational treatments span various therapeutic areas, encompassing psychiatry, neurology, and non-central nervous system conditions like gastrointestinal, oncological, and cardiovascular disorders. Founded in 2013, Pear Therapeutics, Inc. is headquartered in Boston, Massachusetts.